A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 127, Issue 3, 2012, Pages 538-543

  Coleman, Robert L ^a   Sill, Michael W ^b   Lankes, Heather A ^b   Fader, Amanda Nickles ^c   Finkler, Neil J ^d   Hoffman, James S ^e   Rose, Peter G ^f   Sutton, Gregory P ^g   Drescher, Charles W ^h   McMeekin, D Scott ⁱ   Hu, Wei ^a   Deavers, Michael ^a   Godwin, Andrew K ^j   Alpaugh, R Katherine ^k   Sood, Anil K ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d FLORIDA HOSPITAL CANCER INSTITUTE   (United States)

^e NEW BRITAIN GENERAL HOSPITAL   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g ST VINCENT HOSPITAL   (United States)

^h Pacific Gynecology Specialists   (United States)

ⁱ UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^j UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^k FOX CHASE CANCER CENTER   (United States)

more..

Author keywords

Aflibercept; Endometrial cancer; Fibroblast growth factor; Toxicity; VEGF Trap

Indexed keywords

AFLIBERCEPT; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 8; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ANEMIA; ARTERY RUPTURE; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; COGNITION; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DYSPNEA; ENDOMETRIUM CANCER; EYE DISEASE; FEMALE; HEART FAILURE; HUMAN; HYPERTENSION; HYPONATREMIA; IMMUNOHISTOCHEMISTRY; INFECTION; LEUKOENCEPHALOPATHY; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RECURRENT CANCER; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; TREATMENT RESPONSE; VEIN THROMBOSIS; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECOMBINANT FUSION PROTEINS;

EID: 84868588283     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.08.020     Document Type: Article

References (25)

1. L.R. Duska, R. Berkowitz, U. Matulonis, M. Muto, A. Goodman, and J.F. McIntyre A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with high-risk endometrial cancer Gynecol Oncol 96 2005 198 203
2. J.T. Thigpen, M.F. Brady, H.D. Homesley, J. Malfetano, B. DuBeshter, and R.A. Burger Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group study J Clin Oncol 22 2004 3902 3908
3. J.T. Soper, S.A. Reisinger, R. Ashbury, E. Jones, and D.L. Clarke-Pearson Feasibility study of concurrent weekly cisplatin and whole abdominopelvic irradiation followed by doxorubicin/cisplatin chemotherapy for advanced stage endometrial carcinoma: a Gynecologic Oncology Group trial Gynecol Oncol 95 2004 95 100
4. G.F. Fleming, V.L. Brunetto, D. Cella, K.Y. Look, G.C. Reid, and A.R. Munkarah Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study J Clin Oncol 22 2004 2159 2166
5. A.A. Kamat, W.M. Merritt, D. Coffey, Y.G. Lin, P.R. Patel, and R. Broaddus Clinical and biological significance of vascular endothelial growth factor in endometrial cancer Clin Cancer Res 13 2007 7487 7495
6. A. Talvensaari-Mattila, Y. Soini, and M. Santala VEGF and its receptors (flt-1 and KDR/flk-1) as prognostic indicators in endometrial carcinoma Tumour Biol 26 2005 81 87
7. B.A. Fine, P.T. Valente, G.I. Feinstein, and T. Dey VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma Gynecol Oncol 76 2000 33 39
8. R. Fujiwaki, K. Hata, K. Iida, Y. Maede, Y. Watanabe, and M. Koike Co-expression of vascular endothelial growth factor and thymidine phosphorylase in endometrial cancer Acta Obstet Gynecol Scand 78 1999 728 734
9. Y. Yokoyama, D.S. Charnock-Jones, D. Licence, A. Yanaihara, J.M. Hastings, and C.M. Holland Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma Clin Cancer Res 9 2003 1361 1369
10. E. Sivridis, A. Giatromanolaki, P. Anastasiadis, L. Georgiou, K.C. Gatter, and A.L. Harris Angiogenic co-operation of VEGF and stromal cell TP in endometrial carcinomas J Pathol 196 2002 416 422
11. A. Giatromanolaki, E. Sivridis, R. Brekken, P.E. Thorpe, P. Anastasiadis, and K.C. Gatter The angiogenic vascular endothelial growth factor/flk-1(KDR) receptor pathway in patients with endometrial carcinoma: prognostic and therapeutic implications Cancer 92 2001 2569 2577
12. C.A. Chen, W.F. Cheng, C.N. Lee, L.H. Wei, J.S. Chu, and F.J. Hsieh Cytosol vascular endothelial growth factor in endometrial carcinoma: correlation with disease-free survival Gynecol Oncol 80 2001 207 212
13. M. Hirai, A. Nakagawara, T. Oosaki, Y. Hayashi, M. Hirono, and T. Yoshihara Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma Gynecol Oncol 80 2001 181 188
14. C. Aghajanian, M.W. Sill, K.M. Darcy, B. Greer, D.S. McMeekin, and P.G. Rose Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study J Clin Oncol 29 2011 2259 2265
15. J. Holash, S. Davis, N. Papadopoulos, S.D. Croll, L. Ho, and M. Russell VEGF-Trap: a VEGF blocker with potent antitumor effects Proc Natl Acad Sci U S A 99 2002 11393 11398
16. E.S. Kim, A. Serur, J. Huang, C.A. Manley, K.W. McCrudden, and J.S. Frischer Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma Proc Natl Acad Sci U S A 99 2002 11399 11404
17. E. van Cutsem, J. Tabernero, R. Lakomy, J. Prausova, P. Ruff, and G. Van Hazel Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): results of a multinational phase III trial (EFC 10262-VELOUR) Ann Oncol 22 2011 v18 (O-0024)
18. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada [see comment] J Natl Cancer Inst 92 2000 205 216
19. D.C. Allred, J.M. Harvey, M. Berardo, and G.M. Clark Prognostic and predictive factors in breast cancer by immunohistochemical analysis Mod Pathol 11 1998 155 168
20. M.W. Sill, and G. Yothers A method for utilizing bivariate efficacy outcome measures to screen agents for activity in 2-stage phase II clinical trials Technical Report 06-08 (ed 2008) 2008 Department of Biostatistics, University of Buffalo Buffalo
21. D.R. Cox Regression models and life tables J R Stat Soc B 34 1972 187 220
22. G.J. Hahn, and W.Q. Meeker Statistical intervals: a guide for practitioners 1991 John Wiley & Sons New York
23. R.L. Coleman, L.R. Duska, P.T. Ramirez, J.V. Heymach, A.A. Kamat, and S.C. Modesitt Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer Lancet Oncol 12 2011 1109 1117
24. M.J. Birrer, M.E. Johnson, K. Hao, K.K. Wong, D.C. Park, and A. Bell Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas J Clin Oncol 25 2007 2281 2287
25. R. Cao, E. Brakenhielm, R. Pawliuk, D. Wariaro, M.J. Post, and E. Wahlberg Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2 Nat Med 9 2003 604 613